Author

Nervin Lawendy 1

1 Pfizer Inc,Collegeville,United States

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Bruce E. Sands, Walter Reinisch, Julian Panés, Paulo Gustavo Kotze, Donna T Judd, Rajiv Mundayat, Nervin Lawendy

An update on the analysis of non-melanoma skin cancer in the tofacitinib ulcerative colitis programme

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme

William Sandborn, Julian Panés, Bruce E. Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese

INTEGRATED SAFETY ANALYSES OF TOFACITINIB IN ULCERATIVE COLITIS CLINICAL TRIALS

William Sandborn, Julian Panés, Geert R. D'Haens, Bruce E. Sands, Chinyu Su, Michele Moscariello, Thomas V Jones, Ron Pedersen, Gary S. Friedman, Nervin Lawendy, Gary Chan

Laboratory parameters related to monitoring in patients with ulcerative colitis treated with tofacitinib for up to 3 years in the OCTAVE open-label, long-term extension study

Gil Y. Melmed, Shannon Chang, nicole kulisek, Haiyun Fan, Nervin Lawendy, Eric Maller, Arif Soonasra, Peter Irving

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

Predictors of delayed response to tofacitinib: results of the octave open study for delayed responders

Miguel Regueiro, Jami A. Kinnucan, Ryan Ungaro, Daniel Quirk, Chinyu Su, Nervin Lawendy, Haiyun Fan, Deborah.A Woodworth, Markus F. Neurath

Item 1 - 10 / 24
1
2 3